Bernd Hentsch

Directeur/Bestuurslid bij G2M Cancer Drugs AG

64 jaar

Retail Trade

Commercial Services

Health Technology

Actieve functies van Bernd Hentsch

Bedrijven	Functie	Begin	Einde
G2M Cancer Drugs AG G2M Cancer Drugs AG Miscellaneous Commercial ServicesCommercial Services Part of Valerio Therapeutics SA, G2M Cancer Drugs AG is a German company that researches new anti-cancer therapeutics and develops selected late-stage products. The company is based in Frankfurt am Main, Germany. G2M Cancer Drugs was acquired by Topotarget A/S on March 01, 2005.	Directeur/Bestuurslid	01-01-2001	-

Bedrijven	Functie	Begin	Einde
4SC AG	Corporate Officer/Principal	11-05-2010	-
TopoTarget UK Ltd. TopoTarget UK Ltd. Drugstore ChainsRetail Trade TopoTarget UK Ltd. engages in the discovery and development of drugs and therapies to treat cancer. It develops anti-cancer drugs for molecular mechanisms associated with the cell cycle, chromatin control and DNA damage. The company was founded in 2002 and is headquartered in Oxford, the United Kingdom.	Corporate Officer/Principal	-	-

Julius-Maximilians-Universität Würzburg

Doctorate Degree

Internationaal

Duitsland	4
Verenigd Koninkrijk	2

Operationeel

Corporate Officer/Principal	2
Director/Board Member	1
Doctorate Degree	1

Sectoraal

Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Beursgenoteerde bedrijven	1
4SC AG	Health Technology

Bedrijven in privébezit	2
TopoTarget UK Ltd. TopoTarget UK Ltd. Drugstore ChainsRetail Trade TopoTarget UK Ltd. engages in the discovery and development of drugs and therapies to treat cancer. It develops anti-cancer drugs for molecular mechanisms associated with the cell cycle, chromatin control and DNA damage. The company was founded in 2002 and is headquartered in Oxford, the United Kingdom.	Retail Trade
G2M Cancer Drugs AG G2M Cancer Drugs AG Miscellaneous Commercial ServicesCommercial Services Part of Valerio Therapeutics SA, G2M Cancer Drugs AG is a German company that researches new anti-cancer therapeutics and develops selected late-stage products. The company is based in Frankfurt am Main, Germany. G2M Cancer Drugs was acquired by Topotarget A/S on March 01, 2005.	Commercial Services